IMRN - Immuron rises ~10% on getting European patent for drug composition to treat bacterial infection

• Immuron ( NASDAQ: IMRN ) said it received a European Patent for compositions and methods for treating and/or preventing Clostridioides difficile associated disease.
• The Patent 14784945.9 titled 'Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease,' was formally received yesterday. The company had announced in July 2022 that it would get this patent.
• The European registration adds to Immuron's patent position in Australia, New Zealand and the U.S., the company noted.
• Clostridioides difficile infection is a disease of the large intestine caused by toxins produced by the spore forming bacterium Clostridioides difficile.
• IMRN +12.50% to $2.25 premarket Jan. 17

For further details see: